Nintedanib and Dasatinib Treatments Induce Protective Autophagy as a Potential Resistance Mechanism in MPM Cells
Malignant pleural mesothelioma (MPM) is a rare type of cancer with a grim prognosis.So far, no targetable oncogenic mutation was identified in MPM and Extractors biomarkers with predictive value toward drug sensitivity or resistance are also lacking.Nintedanib (BIBF1120) is a small-molecule tyrosine kinase inhibitor that showed promising efficacy p